Stuart Madden, PhD, CChem, FRSC
Chief Scientific Officer
Stuart Madden has over 30 years of experience in the pharmaceutical industry working on drug development programs, from proof of concept through to commercialization for New Chemical Entity (NCE) and 505(b)(2) products that have encompassed small molecules, biologics, and combination products. Dr. Madden has worked with Neurelis since 2008, supporting the development of VALTOCO and, in July 2020, joined Neurelis as a full-time employee. Since 2003 and prior to joining Neurelis, Dr. Madden was Vice President of Scientific Affairs at ICON Clinical Research where his role was providing strategic consulting expertise to biotech and pharmaceutical clients in optimizing their development programs. From 1995 to 2003, Dr. Madden worked for Elan Corporation, a specialty drug delivery company specializing in the development and commercialization of controlled-release oral dosage forms. Earlier in his career, Dr. Madden worked in large pharma, including Mallinckrodt and Schering Plough. Dr. Madden received his BS degree in chemistry and his PhD in physical chemistry from the University of Wales, Swansea, UK, and spent 2 years as a postdoctoral fellow at San Diego State University, California. He is a Chartered Chemist and Fellow of the Royal Society of Chemistry and a past special government employee for FDA's Advisory Committee for Pharmaceutical Science and Clinical Pharmacology.
Stuart Madden, PhD, CChem, FRSC
Chief Scientific Officer
Stuart Madden has over 30 years of experience in the pharmaceutical industry working on drug development programs, from proof of concept through to commercialization for New Chemical Entity (NCE) and 505(b)(2) products that have encompassed small molecules, biologics, and combination products. Dr. Madden has worked with Neurelis since 2008, supporting the development of VALTOCO and, in July 2020, joined Neurelis as a full-time employee. Since 2003 and prior to joining Neurelis, Dr. Madden was Vice President of Scientific Affairs at ICON Clinical Research where his role was providing strategic consulting expertise to biotech and pharmaceutical clients in optimizing their development programs. From 1995 to 2003, Dr. Madden worked for Elan Corporation, a specialty drug delivery company specializing in the development and commercialization of controlled-release oral dosage forms. Earlier in his career, Dr. Madden worked in large pharma, including Mallinckrodt and Schering Plough. Dr. Madden received his BS degree in chemistry and his PhD in physical chemistry from the University of Wales, Swansea, UK, and spent 2 years as a postdoctoral fellow at San Diego State University, California. He is a Chartered Chemist and Fellow of the Royal Society of Chemistry and a past special government employee for FDA's Advisory Committee for Pharmaceutical Science and Clinical Pharmacology.